Cargando…
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs
Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damag...
Autor principal: | Tanaka, Yoshiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709568/ https://www.ncbi.nlm.nih.gov/pubmed/34951925 http://dx.doi.org/10.1093/rheumatology/keab609 |
Ejemplares similares
-
Unmet needs in rheumatoid arthritis
por: Moreland, Larry
Publicado: (2005) -
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
por: Bektas, Meryem, et al.
Publicado: (2020) -
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019) -
Patient satisfaction with medication in rheumatoid arthritis: an unmet need
por: Miladi, Saoussen, et al.
Publicado: (2023) -
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
por: Tanaka, Yoshiya
Publicado: (2021)